CT26.WT Syngeneic Model Overview
The CT26.WT syngeneic model is one of the most extensively used murine models for preclinical evaluation of immunotherapies targeting colorectal cancer. Derived from a chemically induced, undifferentiated colon carcinoma in BALB/c mice, CT26.WT tumors are highly immunogenic and demonstrate robust, reproducible growth in immunocompetent hosts. The model has become a cornerstone in immuno-oncology research, serving as a standard system for evaluating immune checkpoint blockade, adoptive T-cell therapy, oncolytic viral therapy, and cancer vaccines.
When implanted subcutaneously or orthotopically in BALB/c mice, CT26.WT cells produce fast-growing, vascularized tumors with consistent histopathology and an active immune microenvironment. The model exhibits moderate metastatic potential, most commonly to the lungs and liver, depending on the implantation route. Because it retains full immune competence, CT26.WT allows direct investigation of T-cell activation, cytokine modulation, and tumor–immune cell interactions in response to both monotherapy and combination regimens. Its reproducibility and sensitivity to immune modulation make it a benchmark model for evaluating novel immunotherapeutic strategies against colorectal carcinoma.
Request a Custom Quote for CT26.WT Syngeneic ModelBiological and Molecular Characteristics
The CT26.WT cell line originates from a BALB/c mouse treated with N-nitroso-N-methylurethane, a carcinogen that induces spontaneous colon adenocarcinoma. The line displays an epithelial morphology consistent with poorly differentiated colorectal carcinoma and lacks expression of canonical hormone receptors (ER, PR, HER2). Molecular profiling demonstrates high mutational burden and abundant neoantigen expression, contributing to its strong immunogenicity and robust immune infiltration during tumor progression.
The model expresses elevated levels of cytokines such as IL-6, IFN-γ, and TNF-α, reflecting an active pro-inflammatory microenvironment. CT26.WT tumors also produce VEGF and CXCL1, supporting angiogenesis and immune cell recruitment. The presence of infiltrating CD8⁺ T cells, macrophages, and regulatory T cells establishes a dynamic immune landscape suitable for evaluating therapeutic interventions that modulate immune balance, tumor eradication, and memory formation.
| Parameter | Description |
|---|---|
| Host strain | BALB/c (female, 6–8 weeks) |
| Tumor origin | Chemically induced colon carcinoma (mouse) |
| Histological type | Undifferentiated adenocarcinoma |
| Inoculation route | Subcutaneous, orthotopic, or intravenous |
| Tumor take rate | >95% |
| Doubling time | Approximately 2–3 days in vivo |
| Metastatic potential | Moderate; lung and liver metastases possible |
| Immunophenotype | Strongly immunogenic, rich in CD8⁺ and macrophage infiltration |
| Common applications | Checkpoint blockade, vaccine therapy, adoptive T-cell studies |
In Vivo Model Development and Tumorigenicity
The CT26.WT syngeneic model is typically established through subcutaneous injection of tumor cells into BALB/c mice, resulting in consistent and rapid tumor formation within 4–6 days post-inoculation. Orthotopic implantation into the cecal wall can also be employed to mimic local tumor growth and spontaneous metastasis to regional lymph nodes and the liver. Intravenous injection produces disseminated metastases, most commonly in the lungs, and is frequently used for metastasis and immunotherapy efficacy studies.
Tumor growth kinetics are highly reproducible, and measurable lesions can be used for therapeutic testing within one week of implantation. The CT26.WT model is particularly suitable for evaluating T-cell–dependent immune responses, the efficacy of checkpoint inhibitors, and the development of systemic immune memory following tumor regression. Because the model exhibits strong immunogenicity and moderate growth rates, it provides an ideal setting for comparative analyses of innate and adaptive immune modulation across multiple therapeutic modalities.
Request a Custom Quote for CT26.WT Syngeneic ModelHistopathology and Immunohistochemical Profile
Histological examination of CT26.WT tumors reveals sheets of undifferentiated epithelial cells with large, hyperchromatic nuclei, high mitotic index, and minimal glandular organization. The tumors are moderately vascularized, with stromal regions densely infiltrated by macrophages, lymphocytes, and neutrophils. Necrotic foci are frequently present in larger tumors, accompanied by prominent perivascular inflammation.
Immunohistochemical staining demonstrates extensive Ki-67 positivity, reflecting rapid proliferation. CD3 and CD8 markers confirm significant T-cell infiltration throughout the tumor parenchyma, while F4/80 staining highlights macrophage populations concentrated at the invasive margins. PD-L1 expression is variable, frequently upregulated in response to interferon signaling, and localized to both tumor and immune cells. The histopathological features of CT26.WT tumors—high cellular turnover, angiogenesis, and dense immune cell infiltration—closely resemble the inflammatory microenvironment observed in human colorectal carcinomas, supporting its relevance for translational research.
Preclinical Applications and Drug Response
The CT26.WT syngeneic model is among the most frequently used systems for immuno-oncology drug development due to its reproducibility, immunogenicity, and translational relevance. It has demonstrated responsiveness to a variety of immunotherapeutic approaches, including checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4, as well as adoptive T-cell and dendritic cell–based vaccines. Treatment with anti-PD-1 or anti-CTLA-4 antibodies induces partial or complete regressions in a subset of mice, often accompanied by durable immune memory and resistance to tumor re-challenge.
Combination therapies involving checkpoint inhibitors and cytokine modulators, such as IL-2 or GM-CSF, have further enhanced therapeutic outcomes in this model. Chemotherapy agents like oxaliplatin or 5-fluorouracil have also been evaluated for their ability to promote immunogenic cell death and potentiate immune-mediated tumor clearance. Because of its strong immune responsiveness and established research history, the CT26.WT model continues to serve as a gold standard for testing immunotherapeutic mechanisms, biomarker discovery, and combination strategies targeting colorectal cancer.
Request This Model
To request the CT26.WT syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for CT26.WT Syngeneic Model